MDBH vs HIVE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 21, 2026

MDBH

49.8
AI Score
VS
HIVE Wins

HIVE

57.7
AI Score

Investment Advisor Scores

MDBH

50score
Recommendation
HOLD

HIVE

58score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric MDBH HIVE Winner
Net Income -16.05M -148.45M MDBH
ROE -32.3% -28.0% HIVE
ROA -31.6% -23.2% HIVE
Total Assets 50.77M 639.15M HIVE
Cash 9.58M 23.11M HIVE

Relative Price Performance (Last 90 Days)

MDBH 1M: -35.6% · 3M: -47.2% HIVE 1M: -41.5% · 3M: -34.6%

Current Technical Phase

MDBH

Markdown
Sell / avoid

Price below a falling SMA50 (slope -14.1%), weak momentum, RSI 29

RSI (14): 28.7 · Price: $1.72

HIVE

Markdown
Sell / avoid

Price below a falling SMA50 (slope -5.3%), weak momentum, RSI 24

RSI (14): 23.7 · Price: $1.93

Fundamentals Snapshot

Metric MDBH HIVE
Market Cap — —
Forward P/E 0.0 -3.8
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.9% 0.7%
Gross Margin 0.7% 0.4%
Operating Margin 11.1% -0.6%
EPS -2.14 -1.32
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, HIVE is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.